Clinical Trial

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-12-22; most recent amendment 2026-07-02.
Trial Details
NCT Number NCT07319871
Lead Sponsor Janssen Research & Development, LLC
Conditions Prostatic Neoplasms
Enrollment 40 participants
Start Date 2026-01-14
Primary Completion 2027-01-07 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-06